This is a working overview of GHS-R1a, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-21. Anything still debated is marked as such rather than presented as settled.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
== 1942: Battle of Stalingrad == On 1 January 1942, the 4th Panzer Group was redesignated 4th Panzer Army. The 4th Panzer Army held defensive positions in the spring of 1942 and then was reinforced, re-fit and transferred to Army Group South for Case Blue, its offensive in Southern Russia. Command was transferred to general Hermann Hoth in June. As the operation progressed, Hitler divided Army Group South into two army groups. Army Group A which was composed of the German 17th Army and 1st Panzer Army and Army Group B which was composed of 6th Army and the 4th Panzer Army. The 4th Panzer Army was on 1 Aug 1942 composed of:
==== Improvement in batteries ==== Improvements can be seen in the electrical conductivity and charge retention of batteries when QDs are added to anodes. In a comparison made between Pure MnO and MnO doped with quantum dot for the capacity of charge and discharge in (mAh/g) against the number of cycles, it can be seen that battery capacity, or the amount of energy that a battery can hold, is higher in MnO quantum dot-doped batteries than in batteries without, and remains higher after many charging/discharging cycles, taking in consideration a current density of Ag^-1. There exists a constant average difference of around 250 mAh/g in favor of the doped compound for both charge and discharge comparisons, comparing from 0 to 60 cycles, going from 1000 mAh/g to 450 mAh/g in the first 60 cycles for the doped compound, and from 750 mAh/g to 200 mAh/g for the pure MnO. A comparison using Graphene Quantum Dots for a NP-SiAl compound not only shows higher discharge capacities but also an improved electrochemical impedance spectroscopy plot, indicating that the battery has better electrical conductivity. For the case of the NP-SiAl/GQDs, the value of -Z´´/ohm reaches a peak of 300, for 250 Z´/ohm, while for the pure NP-SiAl, the peak of 300 -Z´´/ohm is reached at 650 Z´/ohm.
== Trial == Dias' trial started in November 2011. Alcina Dias identified him in court. On 3 October 2014, Dias, was sentenced to three years in jail for the kidnapping of Mendonça during the afternoon of his disappearance. On 18 March 2015, Dias was led to jail by his lawyer, after his arrest warrant had been issued. His sentence was reduced to two years for good behavior. On 29 March 2017, Dias was released.
The release of alarm pheromones near a hive may attract other bees to the location, where they will likewise exhibit defensive behaviors until there is no longer a threat, typically because the victim has either fled or been killed. (Note: A bee swarm, seen as a mass of bees flying or clumped together, is generally not hostile; it has deserted its hive and has no comb or young to defend.) These pheromones do not dissipate or wash off quickly, and if their target enters the water, bees will resume their attack as soon as it leaves the water. The alarm pheromone emitted when a bee stings another animal smells like a banana. Drone bees, the males, are larger and do not have stingers. The female bees (worker bees and queens) are the only ones that can sting, and their stinger is a modified ovipositor. The queen bee has a barbed but smoother stinger and can, if need be, sting skin-bearing creatures multiple times, but the queen does not leave the hive under normal conditions. Her sting is not for the defense of the hive; she only uses it for dispatching rival queens, ideally before they can emerge from their cells. Queen breeders who handle multiple queens and have the queen odor on their hands are sometimes stung by a queen. The stinger consists of three parts: a stylus and two barbed slides (or lancets), one on either side of the stylus. The bee does not push the stinger in but it is drawn in by the barbed slides.
=== Food adulterant === Melamine is sometimes illegally added to food products in order to increase the apparent protein content. Standard tests, such as the Kjeldahl and Dumas tests, estimate protein levels by measuring the nitrogen content, so they can be misled by the addition of nitrogen-rich, but non-proteinaceous compounds such as melamine. There are instruments available today that can differentiate melamine nitrogen from protein nitrogen.
Sources: en.wikipedia.org
A third type of hallucinogenic mushroom is hallucinogenic bolete mushrooms such as Lanmaoa asiatica, which are said to cause people to experience Lilliputian hallucinations. These mushrooms have unknown constituents and an unknown mechanism of action, but appear to be distinct in their properties and effects from other hallucinogenic mushrooms and are currently being researched.
The scenario of a large unification of civilizations over an extent of 1 to 10 billion light-years with concentration in a certain region has a probability of 60%. These civilizations are to be searched for in the most powerful quasars and in the galactic bulge, at a radiation level higher than 1038 W, in the wavelengths from 10 μm to 10 cm, as well as in the other regions of the spectrum. This is to detect megastructures or signals with a wavelength of 1.5 mm and omnidirectional emission up to 21 cm. In the event of contact, humanity would see progress in all areas of society in order to join this supercivilization; it is also expected that an ethnographic conservatory would be created on Earth. The scenario of a unification on the scale of the galactic cluster has only a 20% probability of realization. Kardashev advises to observe the Virgo cluster (especially M87) and other clusters in a similar way as in the first scenario. The consequences for humanity are the same as in the first scenario. The scenario of a unification on the scale of galaxies has only a 10% probability. To confirm it, we must study the galactic centers, both of the Milky Way and of neighboring galaxies (such as M31, M33), according to a procedure similar to that of the first scenario. The consequences for humanity are the same as in the first scenario. The scenario of a complete colonization of space has no probability of being realized according to Kardashev because if it were realizable then "they" would already be on Earth; yet this is not the case.
== Classification == Hypermobility spectrum disorders are diagnosed when individuals have symptomatic joint hypermobility but do not meet the criteria for other connective tissue disorders, such as Ehlers–Danlos syndrome. In March 2017, the International Consortium on the Ehlers-Danlos Syndromes published a revised classification naming two syndromes: hypermobile EDS (hEDS), which has narrowly defined criteria, and hypermobility spectrum disorder (HSD) for those with some but not all the features of hEDS. This reclassification aimed to address the overlap between joint hypermobility syndrome and what was previously termed EDS-hypermobile type (EDS-HT). Patients who have a diagnosis of EDS-HT or JHS will fall into one of these two new categories. Hypermobility spectrum disorder does not include people with asymptomatic hypermobility or people with double-jointedness but no other symptoms. Hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders may be equally severe. HSD is further classified into different subtypes, which include:
Erectile dysfunction (ED), also referred to as impotence, is a form of sexual dysfunction in males characterized by the persistent or recurring inability to achieve or maintain a penile erection with sufficient rigidity and duration for satisfactory sexual activity. It is the most common sexual problem in males and can cause psychological distress due to its impact on self-image and sexual relationships. The term erectile dysfunction does not encompass other erection-related disorders, such as priapism. The majority of ED cases are attributed to physical risk factors and predictive factors. These factors can be categorized as vascular, neurological, local penile, hormonal, and drug-induced. Notable predictors of ED include aging, cardiovascular disease, diabetes mellitus, high blood pressure, obesity, abnormal lipid levels in the blood, hypogonadism, smoking, depression, and medication use. Approximately 10% of cases are linked to psychosocial factors, encompassing conditions such as depression, stress, and problems within relationships. ED is reported in 18% of males aged 50 to 59 years, and 37% in males aged 70 to 75. Treatment of ED encompasses addressing the underlying causes, lifestyle modification, and addressing psychosocial issues. In many instances, medication-based therapies are used, specifically PDE5 inhibitors such as sildenafil. These drugs function by dilating blood vessels, facilitating increased blood flow into the spongy tissue of the penis, analogous to opening a valve wider to enhance water flow in a fire hose.
Sources: en.wikipedia.org
Existential risk researchers analyze risks that could lead to human extinction or civilizational collapse, and look for ways to build resilience against them. Relevant research centers include the Cambridge Center for the Study of Existential Risk and the Stanford Existential Risk Initiative. Future technologies may contribute to the risks of artificial general intelligence, biological warfare, nuclear warfare, nanotechnology, anthropogenic climate change, global warming, or stable global totalitarianism, though technologies may also help to mitigate asteroid impacts and gamma-ray bursts. In 2019, philosopher Nick Bostrom introduced the notion of a vulnerable world, "one in which there is some level of technological development at which civilization almost certainly gets devastated by default", citing the risks of a pandemic caused by bioterrorists, or an arms race triggered by the development of novel armaments and the loss of mutual assured destruction. He invites policymakers to question the assumptions that technological progress is always beneficial, that scientific openness is always preferable, or that they can afford to wait until a dangerous technology has been invented before they prepare mitigations.
The International History Review. 30 (4): 709–740. doi:10.1080/07075332.2008.10416646. ISSN 1949-6540. JSTOR 40213728. S2CID 153677447. Panzac, Daniel (1995). Histoire économique et sociale de l'Empire ottoman et de la Turquie (1326-1960). Peeters Publishers. ISBN 90-6831-799-7. Pappé, Ilan (2006). The Ethnic Cleansing of Palestine. Oneworld. ISBN 978-1-85168-555-4. Reilly, James A. (2016). The Ottoman Cities of Lebanon: Historical Legacy and Identity in the Modern Middle East. London: I. B. Tauris. ISBN 978-1-78672-036-8. Salibi, Kamal S. (January 1961). "The Buḥturids of the Garb. Mediaeval Lords of Beirut and of Southern Lebanon". Arabica. 8 (1): 74–97. doi:10.1163/157005861X00043. JSTOR 4054971. Salibi, K. (1965). "Fakhr al-Dīn". In Lewis, B.; Pellat, Ch. & Schacht, J. (eds.). The Encyclopaedia of Islam, Second Edition. Volume II: C–G. Leiden: E. J. Brill. pp. 749–751. OCLC 495469475. Salibi, K. (February 1968). "The muqaddams of Bšarrī: Maronite chieftains of the Northern Lebanon 1382–1621". Arabica. 15 (1): 63–86. doi:10.1163/157005868X00280. ISSN 0570-5398. JSTOR 4056124. Salibi, K. (2005). A House of Many Mansions: The History of Lebanon Reconsidered. London: I.B. Tauris. ISBN 978-1-86064-912-7. Salibi, Kamal Suleiman (2005b). The Druze: Realities & Perceptions. University of Michigan Press. ISBN 978-1-904850-06-9. Schilcher, L. Schatkowski (1981). "The Hauran Conflicts of the 1860s: A Chapter in the Rural History of Modern Syria". International Journal of Middle East Studies. 13 (2): 159–179. doi:10.1017/S0020743800055276. JSTOR 162818. S2CID 162263141.
The table delineates the mineral content corresponding to each genotype. Regarding calcium content, mashua exhibits a lower concentration than potatoes, with the latter containing approximately 13,100 mg/100 g dry matter. In contrast, the phosphorus content of mashua is considerably higher than that of potatoes, which have a mere 0.23 mg/100 g dry matter. While potatoes present a significant amount of potassium at 500 mg/100 g dry matter, which surpasses the levels found in purple mashua tubers, they still hold merely a third of the potassium content when contrasted with yellow and yellow-purple mashua varieties. In addition to carotenoids, it also contains phenolic compounds such as gallic acid, anthocyanins and flavonoids.
== Education and career == Turner holds a Bachelor of Medicine and Surgery (MBChB), a Diploma of Obstetrics Gynaecology and Family Planning (Dip Obs) and a Masters of Public Health (MPH Hons) from the University of Auckland. She was awarded a Diploma of Paediatrics (DHC) by the UK Royal College of Physicians. In 2014, the University of Auckland awarded Turner a Doctorate of Medicine (MD) for a thesis titled Factors associated with immunisation coverage for the childhood immunisation programme in New Zealand: 1999–2012. In 1997, in response to low immunisation coverage and equity gaps in the New Zealand immunisation programmes, Turner developed the Immunisation Advisory Centre, (IMAC) an organisation situated at the University of Auckland, that nationally provides independent and factual research-based scientific information regarding vaccine-preventable diseases and the benefits and risks of immunisation. Turner noted that at the time the Immunisation Advisory Centre was set up, there was a "vocal and influential anti-vaccination movement reflecting, an absence of trust in science and a primary healthcare system that wasn't very well organised...[but]...as the New Zealand community...got behind this, the angry anti-immunisation stuff [was] a lot less, because immunisation's normalised now as a positive part of raising healthy children. Whereas back then you had to make an active decision to immunise, now you have to make an active decision not to". As of 2023, Turner is Medical Directory for IMAC.
François Hollande, the 24th President of France, made 183 presidential trips to 83 states internationally during his presidency, which began with his inauguration on 15 May 2012 and ended with the inauguration of Emmanuel Macron on 14 May 2017.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.